BCR-ABL inhibitor

BCR-ABL inhibitor

BCR-ABL inhibitors are drugs that inhibit the abnormal tyrosine kinase produced by the BCR-ABL fusion gene, therebyInhibits the proliferation of tumor cells in chronic myeloid leukemia (CML) and some types of acute lymphoblastic leukemia (Ph+ ALL).It is a molecular targeted drug. It is one of the representative drug classes of tyrosine kinase inhibitors (TKIs) and is widely used as a therapy that selectively targets cancer cells. It is alsoSuccess stories of molecular targeted therapyas known, and holds an important position in current drug discovery research and the development of cancer treatment.

Representative examples of BCR-ABL inhibitors

Imatinib

imatinibFirst-generation BCR-ABL inhibitorIt inhibits the proliferation of leukemia cells by blocking BCR-ABL tyrosine kinase activity. It is a representative molecular targeted drug that has greatly improved the treatment outcomes of chronic myeloid leukemia (CML).Contributed significantly to establishing the standard treatment for CML.It is known as a drug used for this purpose.

Dasatinib

Dasatinib isSecond-generation BCR-ABL inhibitors. In addition to the BCR-ABL tyrosine kinase,Also acts on SRC family kinasesIt has been confirmed to be effective even in cases resistant to imatinib, and it is used to treat chronic myeloid leukemia (CML) and certain types of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Nilotinib

Nilotinib isSecond-generation BCR-ABL inhibitorsIt exhibits more potent inhibitory activity by increasing its affinity for BCR-ABL. Efficacy has also been observed in some cases of imatinib resistance.widely used in the treatment of chronic myeloid leukemia (CML)In addition, it is one of the treatment options aimed at achieving a profound molecular therapeutic effect.

Key Challenges in the Development of BCR-ABL Inhibitors

Overcoming Resistance Mutations

In the development of BCR-ABL inhibitors,Drug resistance caused by ABL kinase domain mutations, including the T315I mutationOvercoming this challenge is a key priority. To address this challenge, second- and third-generation BCR-ABL inhibitors have been developed. Furthermore, preclinical evaluations using resistant cell lines and patient-derived models play a crucial role in elucidating new mechanisms of resistance and verifying the efficacy of next-generation drugs.

Addressing Patient-Specific Mechanisms of Resistance

With BCR-ABL inhibitors,Resistance mutations and pathological conditions vary from patient to patient.Therefore, selecting the optimal treatment is crucial. EspeciallyDrug sensitivity differs for each mutation, such as T315IConsequently, there is a need for evaluations that utilize patient-derived cells, patient-derived models such as PDXs, and high-precision biomarkers and genetic analyses. This is an important evaluation strategy for advancing personalized medicine.

How to predict drug efficacy in humans

To predict drug efficacy in humans,Cell lines alone cannot fully predict clinical drug efficacy.Therefore, disease models with high human extrapolation potential are important. In addition, we must take into account the effects on the bone marrow and the immune system, as well as on-target toxicity in the cardiovascular system and other systems; in addition to evaluating drug efficacy,Comprehensive evaluation combining pharmacokinetics and safety assessmentYou are required to do this.

Non-clinical evaluation required for BCR-ABL inhibitors

Build an evaluation system capable of reproducing resistance mechanisms.

Resistance mutations such as T315IThis is a major challenge in the development of BCR-ABL inhibitors. In some cases, standard cell lines alone cannot adequately replicate the resistance observed in clinical settings. Therefore,Resistant cell lines, patient-derived cells, PDX modelsIt is important to evaluate the effectiveness of resistance mechanisms and next-generation inhibitors under near-clinical conditions by combining them. The selection of pathological models according to the development stage and evaluation objective is required.

To evaluate the effect on the target in a multifaceted way.

"Inhibiting BCR-ABL" is not synonymous with "achieving sufficient therapeutic efficacy." We confirm the effect on the target through Target Engagement and evaluate signal suppression and therapeutic efficacy using molecular biomarkers.Combine evaluation of tumor cell proliferation inhibition by pharmacological and pharmacological tests.This allows us to understand the mechanism of action more accurately.

Evaluate pharmacokinetics and pharmacodynamics in combination.

The reason the therapeutic effect is not being fully achieved may be insufficient exposure to the target.This is also possible. Therefore, we assess absorption, distribution, metabolism, and excretion (ADME) through PK evaluation and confirm whether sufficient exposure is achieved based on tissue distribution and drug concentration. By combining pharmacokinetic and efficacy evaluations, we can appropriately differentiate the causes of insufficient efficacy.

Evaluate safety from an early stage

Since BCR-ABL inhibitors are intended for long-term use, safety assessments are extremely important.開発初期から毒性リスクを把握することで後期開発での失敗リスクを低減できるため、hERG試験などによる心血管系への影響評価を実施します。必要に応じて免疫毒性などの安全性評価を組み合わせ、開発段階や薬剤特性に応じた適切な安全性試験を選択することが重要です。

Key points when choosing a contract research organization (CRO) for non-clinical studies

BCR-ABL阻害薬の非臨床試験では、薬効評価から耐性モデルを用いた評価、薬物動態試験、安全性試験まで一貫して実施できる体制が重要です。特に次世代阻害薬の開発では、耐性機構や病態モデルに精通したCROを選ぶことで開発効率や成功率の向上が期待できます。委託先は技術力・専門性・実績を総合的に比較して選定しましょう。